Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Glioblastoma multiforme (GBM) is the most aggressive brain tumour in adults and remains incurable despite multimodal intensive treatment regimens. We present a patient with a recurrent glioblastoma who showed coexpression of the epidermal growth factor receptor mutant variant III (EGFRvIII) and the tumour-suppressor protein PTEN. She was treated with the tyrosine kinase inhibitor erlotinib for four months, achieving a partial response with improvement of neurologic symptoms. A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided.
Custodio
A
A
Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain. anabelencustodio@hotmail.com
Calles
A
A
Pérez-Segura
P
P
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000096:biosynthesis* / Q000235:genetics; D000069347:Erlotinib Hydrochloride; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006044:Goiter, Nodular / Q000150:complications; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis* / Q000235:genetics; D011799:Quinazolines / Q000627:therapeutic use*; D011878:Radiotherapy
D000970:Antineoplastic Agents; D011799:Quinazolines; C410723:epidermal growth factor receptor VIII; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1
15376352
Lancet. 2003 Jul 5;362(9377):62-4
12853203
Science. 2002 Jul 5;297(5578):63-4
12098689
Radiother Oncol. 2004 Sep;72(3):267-73
15450724
J Clin Oncol. 2004 Jan 1;22(1):133-42
14638850
Science. 2004 Aug 20;305(5687):1163-7
15284455
Brain Tumor Pathol. 1998;15(1):53-7
9879464
Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18
22392572
Genes Dev. 2003 Dec 15;17(24):2998-3010
14701871
Neuro Oncol. 2006 Jan;8(1):67-78
16443950
Mol Cell Biol. 2008 Jan;28(2):587-600
18025104
Oncogene. 2004 Jun 3;23(26):4594-602
15077177
Brain Tumor Pathol. 2004;21(2):53-6
15700833
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72
17646646
Clin Cancer Res. 2002 May;8(5):1100-6
12006525
Cancer Res. 2002 Jan 1;62(1):200-7
11782378
Science. 2007 Oct 12;318(5848):287-90
17872411
Science. 2003 Apr 18;300(5618):445-52
12702867
Gene. 2006 Jun 7;374:1-9
16675164
J Neuropathol Exp Neurol. 2004 Jul;63(7):700-7
15290895
Pathol Oncol Res. 2009 Jun;15(2):225-9
18752056
J Clin Oncol. 2009 Feb 1;27(4):579-84
19075262
Oncogene. 2004 Aug 12;23(36):6095-104
15221011
Anticancer Res. 2008 Nov-Dec;28(6A):3729-32
19189657
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10314-9
11504908
Cancer Res. 2007 Jun 15;67(12):5779-88
17575145
Oncogene. 2003 May 8;22(18):2812-22
12743604
Clin Cancer Res. 2003 Jun;9(6):2316-26
12796401
Cancer Res. 2003 Jun 1;63(11):2742-6
12782577
J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56
11504770
Br J Cancer. 2002 May 6;86(9):1518-23
11986789
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Mol Cancer Ther. 2005 Jan;4(1):101-12
15657358
J Clin Oncol. 2009 Mar 10;27(8):1268-74
19204207
N Engl J Med. 2005 Nov 10;353(19):2012-24
16282176
Neurology. 2005 Apr 26;64(8):1444-5
15851741
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Clin Cancer Res. 2005 Feb 15;11(4):1462-6
15746047